PRMA Insights: The Roadmap to Pricing and Reimbursement Success

Scope of the type 2 diabetes report

Comprehensive secondary research, experienced based insight and validation by payors and Key Opinion Leaders (KOLs) across markets underpins prmainsights™: The Roadmap to Pricing and Reimbursement Success in Type 2 Diabetes:

Reporting of the regulatory nominations and key supporting data for the following products:

Apidra

Byetta

Galvus

Januvia

Lantus

Onglyza

Victoza

 

The current pricing and reimbursement landscape for type 2 diabetes in the top 7 major pharmaceutical markets:

US

UK

France

Germany

Spain

Italy

Japan

Reviews of type 2 diabetes clinical guidelines published by the EASD, ADA, NICE, AACA, JDS, HAS, IQwiG,
DDG, the Italian Society of Diabetes and the Association of Diabetologists, the Spanish Ministry of Health, and the Basque Country Government.

The comprehensive review and assessment of all pricing and reimbursement and HTA decisions for Apidra, Byetta, Galvus, Januvia, Lantus, Onglyza, and Victoza in the top seven major pharmaceutical markets.

Find out more about the type 2 diabetes report:

The report delivers         Scope of the report        Authors of the report